Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Summary

The purpose of ZA-301 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T\<300 ng/dL) and normal sperm concentration, compared to changes with placebo. Subjects must not have previously been treated with testosterone products within the last 6 months.

Timeline

Start

2012-08

Primary completion

2013-03

Completion

2013-03

Drugs

Indications